Land: Nederland
Taal: Nederlands
Bron: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
RANOLAZINE 375 mg/stuk
RANOLAZINE 375 mg/stuk
Tablet met verlengde afgifte
CELLULOSE, MICROKRISTALLIJN (E 460) ; COPOLYMEER VAN ETHYLACRYLAAT-METHACRYLZUUR (1:1) ; HYPROLOSE (E 463) ; HYPROMELLOSE (E 464) ; HYPROMELLOSE, Type 2910 (3 - 15 mPa.s) (E 464) ; MACROGOL 8000 ; MAGNESIUMSTEARAAT (E 470b) ; NATRIUMHYDROXIDE (E 524) ; TITAANDIOXIDE (E 171)
Oraal gebruik
2022-07-21
1 BIJSLUITER: INFORMATIE VOOR DE PATIËNT RANOLAZINE STADA ARZNEIMITTEL AG 375 MG, TABLETTEN MET VERLENGDE AFGIFTE RANOLAZINE STADA ARZNEIMITTEL AG 500 MG, TABLETTEN MET VERLENGDE AFGIFTE RANOLAZINE STADA ARZNEIMITTEL AG 750 MG, TABLETTEN MET VERLENGDE AFGIFTE Ranolazine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What [product name] is and what it is used for 2. What you need to know before you take [product name] 3. How to take [product name] 4. Possible side effects 5. How to store [product name] 6. Contents of the pack and other information 1. WHAT [PRODUCT NAME] IS AND WHAT IS USED FOR [product name] is a medicine used in combination with other medicines to treat angina pectoris, which is a chest pain or discomfort that you feel anywhere along the upper part of your body between your neck and upper abdomen, often brought on by exercise or too much activity. You must talk to a doctor if you do not feel better or if you feel worse. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE [PRODUCT NAME] DO NOT TAKE [PRODUCT NAME] - if you are allergic to ranolazine or any of the other ingredients of this medicine listed in section 6 of this leaflet. - if you have severe kidney problems. - if you have moderate or severe liver problems. - if you are using certain medicines to treat bacterial infections (clarithromycin, telithromycin), fungal infections (itraconazole, ketoconazole, voriconazol, posaconazol), HIV infection (protease inhibitors), depression (nefazodone) or heart rhythm disorders (e.g. quinidine, dofetilide, or so Lees het volledige document
1 SAMENVATTING VAN DE PRODUCTKENMERKEN 1. NAAM VAN HET GENEESMIDDEL Ranolazine STADA Arzneimittel AG 375 mg, tabletten met verlengde afgifte Ranolazine STADA Arzneimittel AG 500 mg, tabletten met verlengde afgifte Ranolazine STADA Arzneimittel AG 750 mg, tabletten met verlengde afgifte 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 375 mg of ranolazine. Each tablet contains 500 mg of ranolazine. Each tablet contains 750 mg of ranolazine. For the full list of excipients see section 6.1. 3. PHARMACEUTICAL FORM Prolonged-release tablet. White, oblong, convex, film-coated tablet of dimensions 15 mm x 7.2 mm, with “375“ embossed on one side. White, oblong, convex, film-coated tablet of dimensions 16.5 mm x 8.0 mm, with “500“ embossed on one side. White, oblong, convex, film-coated tablet of dimensions 19 mm x 9.2 mm, with “750“ embossed on one side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS [Product name] is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists). _ _ 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology [product name] is available as 375 mg, 500 mg, and 750 mg prolonged-release tablets. Adults: The recommended initial dose of [product name] is 375 mg twice daily. After 2–4 weeks, the dose should be titrated to 500 mg twice daily and, according to the patient’s response, further titrated to a recommended maximum dose of 750 mg twice daily (see section 5.1). If a patient experiences treatment-related adverse events (e.g. dizziness, nausea, or vomiting), down titration of [product name] to 500 mg or 375 mg twice daily may be required. If symptoms do not resolve after dose reduction, treatment should be discontinued. Concomitant treatment with CYP3A4 and P-glycoprotein (P-gp) inhibitors: Careful dose titration is recommended in patients treated with moderate CYP3A4 inhibitors (e.g. Lees het volledige document